Depression and Nigral Neuron Density in Lewy Body Spectrum Diseases.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
26
01
2021
received:
16
09
2020
accepted:
07
02
2021
pubmed:
11
2
2021
medline:
27
5
2021
entrez:
10
2
2021
Statut:
ppublish
Résumé
Parkinson's disease and other Lewy body spectrum diseases (LBDs) are associated with a specific risk for clinical depression. In the present clinicopathological study with 73 patients with LBD, we observed that the substantia nigra pars compacta dopamine neuron density was markedly lower in patients who had comorbid depression antemortem than in nondepressed patients (1.52 vs 2.32 n/mm
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1046-1050Informations de copyright
© 2021 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-189.
Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000;15:669-677.
Andreasen P, Lönnroos E, von Euler-Chelpin MC. Prevalence of depression among older adults with dementia living in low- and middle-income countries: a cross-sectional study. Eur J Public Health 2014;24:40-44.
Zhang LY, Cao B, Zou YT, et al. Depression and anxiety in multiple system atrophy. Acta Neurol Scand 2018;137:33-37.
Even C, Weintraub D. Is depression in Parkinson's disease (PD) a specific entity? J Affect Disord 2011;139:103-112.
Magnard R, Vachez Y, Carcenac C, et al. What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease? Transl Psychiatry 2016;6:e753.
Remy P, Doder M, Lees A, et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128:1314-1322.
Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-580.
Fearnley JM, Lees AJ. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991;114:2283-2301.
Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59:591-596.
Kostić VS, Agosta F, Petrović I, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology 2010;75:857-863.
Wilson RS, Nag S, Boyle PA, et al. Brainstem aminergic nuclei and late life depressive symptoms. JAMA Psychiatry 2013;70:1320-1328.
Patterson L, Rushton SP, Attems J, et al. Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders. Brain Pathol 2019;29:544-557.
Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65:1863-1872.
Saari L, Kivinen K, Gardberg M, et al. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology 2017;88:1461-1467.
Guillery RW. On counting and counting errors. J Comp Neurol 2002;447:1-7.
Kasanuki K, Heckman MG, Diehl NN, et al. Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease. Mov Disord 2017;32:1584-1593.
Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-474.
Northoff G, Hirjak D, Wolf RC, et al. All roads lead to the motor cortex: psychomotor mechanisms and their biochemical modulation in psychiatric disorders. Mol Psychiatry 2021;26:92-102.
Conio B, Martino M, Magioncalda P, et al. Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders. Mol Psychiatry 2019;25:82-93.
Drui G, Carnicella S, Carcenac C, et al. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease. Mol Psychiatry 2014;19:358-367.